The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
Oral Lichen Planus
About this trial
This is an interventional treatment trial for Oral Lichen Planus focused on measuring Oral Lichen Planus, Corticosteroid, Omega -3
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of OLP (Presence of painful and atrophic-erosive oral Lesions, bilateral, mostly symmetrical lesions, presence of lace-like network of slightly raised white lines).
- Age between 30-60 years
- Ability to complete the present clinical trial.
Exclusion Criteria:
- Pregnant or breast feeding women (pregnancy test for women of child bearing age).
- Lichenoid reactions caused by certain drugs or dental amalgam.
- Therapy for oral lichen planus (OLP) in the 6 months prior to the study.
- Patient doesn't have hepatitis C [after the patients' medical histories were recorded, the patients were given hepatic screening as published elsewhere. 2
- Presence of candidiasis before treatment.
- Patients with pre-existing diabetes or an initial random glucose level exceeding 200 mg/dL before initiating steroid therapy were excluded.
- Hypertensive patients
- Contraindications for corticosteroid use (immunodeficiency or severe heamatological alterations).
Sites / Locations
- October 6 University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
prednisone 50 mg tablet
Omega-3 capsules 1000 mg
This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.